ACAD - ACADIA Pharmaceuticals Inc.
NASDAQ
->
Healthcare
->
Biotechnology
San Diego,
United States
Type: Equity
ACAD price evolution
ACAD
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $194.43 | $103.96 | $116.06 | $296.67 |
| Short term investments | $250.21 | $247.73 | $267.44 | $111.98 |
| Net receivables | $102.35 | $94.53 | $84.16 | $70.25 |
| Inventory | $40.45 | $25.4 | $14.12 | $11.02 |
| Total current assets | $616.13 | $499.17 | $492.63 | $502.85 |
| Long term investments | ||||
| Property, plant & equipment | $56.47 | $55.64 | $57.58 | $59.75 |
| Goodwill & intangible assets | $65.49 | $66.86 | $68.22 | $69.58 |
| Total noncurrent assets | $132.83 | $133.37 | $150.14 | $152.46 |
| Total investments | $250.21 | $247.73 | $267.44 | $111.98 |
| Total assets | $748.96 | $632.54 | $642.77 | $655.3 |
| Current liabilities | ||||
| Accounts payable | $17.54 | $12.31 | $18.81 | $17.42 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $254.25 | $209.6 | $187.94 | $224.3 |
| Long term debt | $47.8 | $48.1 | $49.78 | $51.44 |
| Total noncurrent liabilities | $62.95 | $60.76 | $59.03 | $56.75 |
| Total debt | $47.8 | $48.1 | $49.78 | $51.44 |
| Total liabilities | $317.2 | $270.37 | $246.98 | $281.05 |
| Shareholders' equity | ||||
| Retained earnings | -$2430.84 | -$2476.63 | -$2411.46 | -$2412.57 |
| Other shareholder equity | $0.02 | -$0.32 | -$0.54 | -$0.22 |
| Total shareholder equity | $431.75 | $362.17 | $395.79 | $374.26 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $194.43 | $120.62 | $153.21 | $331.8 |
| Short term investments | $250.21 | $301.98 | $373.27 | $305.93 |
| Net receivables | $102.35 | $63.08 | $65.34 | $50.28 |
| Inventory | $40.45 | $6.64 | $14.1 | $9.68 |
| Total current assets | $616.13 | $507.94 | $617.82 | $717.62 |
| Long term investments | ||||
| Property, plant & equipment | $56.47 | $61.59 | $66.31 | $56.44 |
| Goodwill & intangible assets | $65.49 | $1.11 | ||
| Total noncurrent assets | $132.83 | $79.88 | $82.3 | $65 |
| Total investments | $250.21 | $301.98 | $373.27 | $305.93 |
| Total assets | $748.96 | $587.81 | $700.12 | $782.62 |
| Current liabilities | ||||
| Accounts payable | $17.54 | $12.75 | $6.88 | $8.49 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $254.25 | $125.63 | $96.07 | $105.97 |
| Long term debt | $47.8 | $52.7 | $56.13 | $44.46 |
| Total noncurrent liabilities | $62.95 | $61.77 | $63.16 | $49.64 |
| Total debt | $47.8 | $52.7 | $56.13 | $44.46 |
| Total liabilities | $317.2 | $187.4 | $159.23 | $155.61 |
| Shareholders' equity | ||||
| Retained earnings | -$2430.84 | -$2369.55 | -$2153.58 | -$1985.71 |
| Other shareholder equity | $0.02 | -$0.97 | -$0.19 | $0.04 |
| Total shareholder equity | $431.75 | $400.41 | $540.89 | $627.01 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $231.04 | $211.7 | $165.24 | $118.46 |
| Cost of revenue | $17.89 | $14.62 | $7.46 | $1.67 |
| Gross Profit | $213.15 | $197.08 | $157.78 | $116.8 |
| Operating activities | ||||
| Research & development | $66.74 | $156.96 | $58.77 | $69.14 |
| Selling, general & administrative | $111.47 | $97.89 | $95.97 | $101.23 |
| Total operating expenses | $178.21 | $254.85 | $154.74 | $170.38 |
| Operating income | $34.94 | -$57.78 | $3.04 | -$53.58 |
| Income from continuing operations | ||||
| EBIT | $39.7 | -$52.14 | $6.34 | -$44.94 |
| Income tax expense | -$6.09 | $13.03 | $5.23 | -$1.92 |
| Interest expense | ||||
| Net income | ||||
| Net income | $45.8 | -$65.18 | $1.11 | -$43.02 |
| Income (for common shares) | $45.8 | -$65.18 | $1.11 | -$43.02 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $726.44 | $517.24 | $484.14 | $441.75 |
| Cost of revenue | $41.64 | $10.17 | $10.84 | $10.21 |
| Gross Profit | $684.8 | $507.07 | $473.3 | $431.54 |
| Operating activities | ||||
| Research & development | $351.62 | $361.57 | $239.41 | $319.13 |
| Selling, general & administrative | $406.56 | $369.09 | $396.03 | $388.66 |
| Total operating expenses | $758.18 | $730.66 | $643.74 | $718.13 |
| Operating income | -$73.38 | -$223.6 | -$170.44 | -$286.59 |
| Income from continuing operations | ||||
| EBIT | -$51.04 | -$213.44 | -$167.52 | -$280.97 |
| Income tax expense | $10.25 | $2.53 | $0.35 | $0.61 |
| Interest expense | ||||
| Net income | ||||
| Net income | -$61.29 | -$215.97 | -$167.87 | -$281.58 |
| Income (for common shares) | -$61.29 | -$215.97 | -$167.87 | -$281.58 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | $45.8 | -$65.18 | $1.11 | -$43.02 |
| Operating activities | ||||
| Depreciation | $1.64 | $1.72 | $1.77 | $0.43 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $18.02 | $18.54 | $15.15 | $14.71 |
| Total cash flows from operations | $85.39 | -$58.95 | $8.2 | -$17.93 |
| Investing activities | ||||
| Capital expenditures | -$0.05 | |||
| Investments | -$0.35 | $34.16 | -$154.28 | $192.52 |
| Total cash flows from investing | -$0.35 | $34.11 | -$194.28 | $192.52 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $5.43 | $12.75 | $5.48 | $1.47 |
| Net borrowings | ||||
| Total cash flows from financing | $5.43 | $12.75 | $5.48 | $1.47 |
| Effect of exchange rate | -$0.01 | -$0 | -$0 | |
| Change in cash and equivalents | $90.46 | -$12.1 | -$180.6 | $176.05 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$61.29 | -$215.97 | -$167.87 | -$281.58 |
| Operating activities | ||||
| Depreciation | $5.55 | $2.03 | $3.34 | $2.93 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $66.42 | $68.2 | $63.62 | $84.42 |
| Total cash flows from operations | $16.7 | -$114.03 | -$125.66 | -$136.17 |
| Investing activities | ||||
| Capital expenditures | -$0.05 | -$1.12 | -$7.59 | |
| Investments | $72.05 | $73.24 | -$69.98 | $200.1 |
| Total cash flows from investing | $32 | $73.24 | -$71.1 | $192.51 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $25.13 | $8.2 | $18.16 | $81 |
| Net borrowings | ||||
| Total cash flows from financing | $25.13 | $8.2 | $18.16 | $81 |
| Effect of exchange rate | -$0.02 | $0.01 | $0.01 | -$0.01 |
| Change in cash and equivalents | $73.81 | -$32.59 | -$178.59 | $137.33 |
News
Fundamentals
| Market cap | $2.81B |
|---|---|
| Enterprise value | $2.66B |
| Shares outstanding | 164.65M |
| Revenue | $726.44M |
|---|---|
| EBITDA | -$45.48M |
| EBIT | -$51.04M |
| Net Income | -$61.29M |
| Revenue Q/Q | 69.27% |
| Revenue Y/Y | N/A |
| P/E ratio | -45.86 |
|---|---|
| EV/Sales | 3.67 |
| EV/EBITDA | -58.57 |
| EV/EBIT | -52.20 |
| P/S ratio | 3.87 |
| P/B ratio | 6.51 |
| Book/Share | 2.62 |
| Cash/Share | 1.18 |
| EPS | -$0.37 |
|---|---|
| ROA | -9.15% |
| ROE | -15.67% |
| Debt/Equity | 0.73 |
|---|---|
| Net debt/EBITDA | -2.70 |
| Current ratio | 2.42 |
| Quick ratio | 2.26 |